Approval · Notice of Compliance 32533 · 2024
TEVA-AZITHROMYCIN: Notice of Compliance 32533
Issued January 17, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32533
- Date
- January 17, 2024
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Product Monograph reformatted to the Master Template. Update to the Package Insert
- Canadian reference product
- ZITHROMAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-AZITHROMYCIN | 02267845 | Marketed |
Medicinal ingredients
- AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE 250 MG per TAB